Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Pharmacotherapy of Sickle Cell Disease in Children. Curr Pharm Des 2015;21(39):5660-7 PMID: 26517528

Pubmed ID

26517528

Abstract

Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population. Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.

Author List

Neville KA, Panepinto JA

Author

Julie A. Panepinto MD, MSPH Professor in the Pediatrics department at Medical College of Wisconsin




Scopus

2-s2.0-84957678033   3 Citations

MESH terms used to index this publication - Major topics in bold

Anemia, Sickle Cell
Child
Humans
jenkins-FCD Prod-310 bff9d975ec7f2d302586822146c2801dd4449aad